Antithymocyte	antithymocyte	O	O	OTHERS	I
globulin	globulin	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
D-penicillamine-induced	d-penicillamine-induced	O	O	O	O
aplastic	aplastic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
patient	patient	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
antithymocyte	antithymocyte	O	O	OTHERS	I
globulin	globulin	O	O	OTHERS	I
therapy	therapy	O	O	O	O
for	for	O	O	O	O
aplastic	aplastic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
D-penicillamine	d-penicillamine	O	O	O	O
therapy	therapy	O	O	O	O
is	is	O	O	O	O
described	described	O	O	O	O
.	.	O	O	O	O

Bone	bone	O	O	O	O
marrow	marrow	O	O	O	O
recovery	recovery	O	O	O	O
and	and	O	O	O	O
peripheral	peripheral	O	O	O	O
blood	blood	O	O	O	O
recovery	recovery	O	O	O	O
were	were	O	O	O	O
complete	complete	O	O	O	O
1	1	O	O	O	O
month	month	O	O	O	O
and	and	O	O	O	O
3	3	O	O	O	O
months	months	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
after	after	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
blood	blood	O	O	O	O
transfusion	transfusion	O	O	O	O
or	or	O	O	O	O
other	other	O	O	O	O
therapies	therapies	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
necessary	necessary	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
follow-up	follow-up	O	O	O	O
period	period	O	O	O	O
of	of	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
2	2	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Use	use	O	O	O	O
of	of	O	O	O	O
antithymocyte	antithymocyte	O	O	OTHERS	I
globulin	globulin	O	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
the	the	O	O	O	O
optimal	optimal	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
D-penicillamine-induced	d-penicillamine-induced	O	O	O	O
aplastic	aplastic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

